Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-09-23 pm EDT
44.08 USD   -1.10%
09/24Pfizer CEO tests positive for COVID
RE
09/23Healthcare Shares Slip But Perform Better Than Broader Market -- Healthcare Roundup
DJ
09/23Pfizer to Supply Global Fund Up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

08/15/2022 | 07:47am EDT

NEW YORK - Pfizer Inc. (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.

The study had two co-primary objectives, associated with immunogenicity responses one month after the third and fourth doses of the four-dose vaccination series, respectively: non-inferiority (NI) of the percentage of participants with predefined serotype-specific immunoglobin G (IgG) concentrations after Dose 3 and NI of IgG geometric mean concentrations (GMCs) after Dose 4. All 20 serotypes met the co-primary objective of NI of IgG GMCs after Dose 4. Fourteen of the 20 serotypes met the co-primary objective of NI of the percentage of participants with predefined IgG levels after Dose 3 (two serotypes missed by a wider margin while four narrowly missed), and all serotypes met noninferiority for the key secondary objective of IgG GMCs after Dose 3. All 20 serotypes elicited robust functional responses (OPA) and increases in antibody responses after Dose 4, with the totality of data supporting the potential benefit of all serotypes in this 20-valent vaccine candidate.

'We are encouraged by today's data which show that if approved for a pediatric indication, 20vPnC would have the potential to cover more of the clinically significant remaining burden of infant pneumococcal disease than any other available pneumococcal conjugate vaccine,' said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. 'We are grateful to everyone who made this study possible, including the study investigators and in particular the trial participants and their parents/guardians for their contribution to this important research.'

Overall, the safety profile of the 20vPnC candidate was consistent with Prevnar 13 given in the same schedule. A similar percentage of infants receiving either vaccine experienced local reactions (pain at the injection site, redness, and swelling), fever, and other systemic events (decreased appetite, drowsiness, and irritability). The study also met non-inferiority objectives for responses to co-administered routinely used pediatric vaccines.

Based on the totality of positive safety and immunogenicity data, Pfizer plans to submit a supplemental Biologics License Application (sBLA) by the end of this year, subject to discussions with the U.S. Food and Drug Administration. Pfizer will seek to present and publish outcomes from this clinical trial at a future date once safety and immunogenicity data have been fully analyzed. Additional top-line results from other pediatric 20vPnC clinical trials are expected to read out in the second half of 2022, with discussions with other regulatory bodies planned once those pivotal data become available.

About the 20vPnC Phase 3 Pediatric Program

In 2020, Pfizer initiated the Phase 3 clinical trial program for the pediatric indication for 20vPnC. Four core Phase 3 pediatric studies will help expand the data on the safety, tolerability, and immunogenicity of 20vPnC. These studies collectively enrolled approximately 4,700 infants and 800 toddlers and children of all ages including:

A Phase 3 study describing the tolerability and safety and comparing immunogenicity of 20vPnC to Prevnar 13 in infants vaccinated at 2, 4, 6, and 12-15 months of age in the U.S. (NCT04382326)

A Phase 3 study describing the tolerability and safety of 20vPnC, with Prevnar 13 serving as the control in infants vaccinated at 2, 4, 6, and 12-15 months of age in multiple countries. (NCT04379713)

A Phase 3 study describing the tolerability and safety and comparing immunogenicity of 20vPnC to Prevnar 13 in infant vaccination at approximately 2, 4, and 11-12 months of age in Europe and Australia (NCT04546425)

A Phase 3 study in children 15 months through

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about PFIZER, INC.
09/24Pfizer CEO tests positive for COVID
RE
09/23Healthcare Shares Slip But Perform Better Than Broader Market -- Healthcare Roundup
DJ
09/23Pfizer to Supply Global Fund Up to 6 Million PAXLOVID Treatment Courses for Low-and-Mid..
AQ
09/23Pfizer To Cut COVID-19 Vaccine Deliveries To COVAX Amid Waning Demand
MT
09/22U.S. cutting global donations of Pfizer COVID shots as demand slows
RE
09/22US Reportedly Amends Pfizer's COVID-19 Vaccine Contract on Waning Demand; Shares Tick D..
MT
09/22Sangamo Therapeutics, Inc. and Pfizer Inc. Provides Update on Giroctocogene Fitelparvov..
CI
09/22GLOBAL MARKETS LIVE : Veolia, Meta, Amazon, Salesforce, Target...
MS
09/22BioNTech-Pfizer Seeks Swissmedic OK for Omicron Subvariant Vaccine
MT
09/22Fed up!
MS
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 739 M - -
Net cash 2022 10 262 M - -
P/E ratio 2022 7,78x
Yield 2022 3,68%
Capitalization 247 B 247 B -
EV / Sales 2022 2,33x
EV / Sales 2023 2,90x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 44,08 $
Average target price 55,75 $
Spread / Average Target 26,5%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-25.35%247 392
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.76%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
NOVO NORDISK A/S1.95%221 838